Wang Min, Huang Shu, Pei Rong, Lin Jie, Yang Xiujiang
Department of Digestive Endoscopy, Jiangsu Province Hospital, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Department of Gastroenterology, the People's Hospital of Lianshui, Huaian 223400, China.
Ann Transl Med. 2019 Dec;7(23):719. doi: 10.21037/atm.2019.11.137.
Endoscopic ultrasonography guided fine needle aspiration (EUS-FNA) is a well-established technique for diagnosing pancreatic malignancy. In general, tissue of pancreatic head and uncinate process lesions is obtained via a transduodenal approach. However, this tissue-acquisition modality is not applicable in cases of pyloric obstruction and duodenal bulb ulceration. The aim of this study is to determine the feasibility and safety of a novel EUS-guided transgastric trans-portal system FNA in the diagnosis of pancreatic head and uncinate process cancer.
This study retrospectively analyzed 26 consecutive inpatient patients who had undergone EUS-FNA for highly suspected malignancy of pancreatic head or uncinate process between December 2013 and December 2018. EUS-guided transgastric trans-portal vein (trans-PV, n=2) or trans-superior mesenteric vein (trans-SMV, n=24) FNA was performed in the patients under conscious sedation. Feasibility, diagnostic yield and complication rates of the technique were evaluated.
Specimens obtained by EUS-guided transgastric trans-portal system FNA were adequate for cytological evaluation in all 26 patients. Cytological diagnosis of adenocarcinoma was established in 22 patients, while the remaining 4 patients were negative. The diagnostic accuracy, sensitivity and specificity were 92.3%, 91.7% and 100% respectively. No immediate or delayed procedure-related complications were observed.
EUS-guided transgastric trans-portal system FNA is a feasible and probably safe method for diagnosing pancreatic head and uncinate process malignancy. Careful selection of the potential candidates and close periprocedural observation are mandatory.
超声内镜引导下细针穿刺抽吸术(EUS-FNA)是诊断胰腺恶性肿瘤的一项成熟技术。一般来说,胰头和钩突部病变组织是通过经十二指肠途径获取的。然而,这种组织获取方式在幽门梗阻和十二指肠球部溃疡的病例中并不适用。本研究的目的是确定一种新型的超声内镜引导下经胃经门静脉系统细针穿刺抽吸术在诊断胰头和钩突部癌症中的可行性和安全性。
本研究回顾性分析了2013年12月至2018年12月期间连续26例因高度怀疑胰头或钩突部恶性肿瘤而接受EUS-FNA的住院患者。在清醒镇静下对患者进行超声内镜引导下经胃经门静脉(经PV,n = 2)或经肠系膜上静脉(经SMV,n = 24)细针穿刺抽吸术。评估该技术的可行性、诊断率和并发症发生率。
通过超声内镜引导下经胃经门静脉系统细针穿刺抽吸术获取的标本在所有26例患者中均足以进行细胞学评估。22例患者细胞学诊断为腺癌,其余4例为阴性。诊断准确性、敏感性和特异性分别为92.3%、91.7%和100%。未观察到与操作相关的即刻或延迟并发症。
超声内镜引导下经胃经门静脉系统细针穿刺抽吸术是诊断胰头和钩突部恶性肿瘤的一种可行且可能安全的方法。必须仔细选择潜在的候选患者并在围手术期密切观察。